source
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…Endpoints · 1mo ago↗ source
- Legend Biotech shares first in vivo CAR-T data, its next act after CarvyktiLegend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field. Legend reported results Tuesday on 12 lymphoma patients from an investigator-initia…Endpoints · 1mo ago↗ source
- FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for PatientsThe U.S. Food and Drug Administration (FDA) today issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific a…